Spatial and Temporal Dynamics of SARS-CoV-2 in COVID-19 Patients – A Systematic Review and Meta-Analysis Published in EBioMedicine
Hellerup, Denmark: UNION therapeutics A/S today announced the publication of a systematic review and meta-analysis of COVID-19 patient’s presence and duration of SARS-CoV-2 virus published in EBioMedicine under The Lancet. The main […]
The Journal of Investigative Dermatology Publish UNION therapeutics’ Phase 2 Clinical Trial Results
ATx201 modulates biomarkers of cutaneous inflammation and skin barrier function in patients with moderate atopic dermatitis Analysis of safety data revealed ATx201 generally safe and well-tolerated in subjects with moderate […]
UNION therapeutics launches COVID-19 program in collaboration with Institut Pasteur Korea
Niclosamide identified as the most potent FDA approved inhibitor of SARS-Cov-2 by Institut Pasteur Korea Potency of niclosamide >25x higher than chloroquine and >40x higher than remdesivir UNION has extensive […]
UNION initiates Phase 2b Dose-Ranging Study Evaluating ATx201 OINTMENT in Patients with Mild-to-Moderate Atopic Dermatitis
Multi-national, double-blinded, and vehicle-controlled study Study expected to enroll approximately 210 patients COPENHAGEN, Denmark: UNION therapeutics A/S (“UNION”), a privately held clinical stage pharmaceutical company dedicated to the discovery and […]
UNION achieves study completion milestone in UNI836 collaboration with Ceva Santé Animale S.A.
Copenhagen, Denmark: UNION therapeutics A/S announced today that a milestone was achieved in its UNI836 collaboration with Ceva Santé Animale S.A. The milestone was triggered by confirmation from Ceva of successful […]
UNION therapeutics A/S Announces Global License Agreement with Ceva Santé Animale S.A.
COPENHAGEN, FEBRUARY 7, 2019 – UNION therapeutics A/S (UNION) today announced that it has entered into a strategic veterinary partnership with Ceva Santé Animale S.A. (Ceva) on the candidate UNI836. Under […]
UNION therapeutics Announces Completion of Phase 2 studies with ATx201
UNION therapeutics A/S (“UNION”), a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today announced results from two positive Phase 2 studies with its lead compound ATx201 […]
UNION therapeutics Announces Successful Phase 1 Study Completion with ATx201
COPENHAGEN, OCTOBER 22, 2018 – UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today announced positive results from a Phase 1 Sensitization Study in 240 […]
AntibioTx Announces Company Name Change to UNION therapeutics
COPENHAGEN, OCTOBER 09, 2018 – Dr. Rasmus Toft-Kehler, Chief Executive Officer of AntibioTx, announced this week in Copenhagen that the company has officially changed its name to UNION therapeutics as […]
AntibioTx Expands Management Team with Dr. Umar Hayat
COPENHAGEN, JULY 01 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Umar Hayat, […]
